Scientific exchange · Dr. Hiroshi Petit

14 Apr 2026 · Virtual · Dr. Hiroshi Petit, MD Anderson Cancer Center · MSL Dr. Anna Becker · Nephrada

ReviewedVeeva CRMENG-0142—

Capture insight from this engagement

Location: MD Anderson Cancer Center
Therapeutic area: Nephrology
Country: United States
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: ABDr. Anna BeckerMSL, Nephrology (DACH)
Product: Nephrada (nephradin)

Topics discussed

Patient-reported outcomes
Proteinuria as surrogate endpoint
Treatment burden and fatigue

Scientific content used

APRIL-IgAN Phase III topline
Surrogate-endpoint evidence review

Questions raised

Is there any data on APRIL inhibition in FSGS?

Notes

Scientific exchange with renal pathologist at MD Anderson Cancer Center. Discussed patient-reported outcomes, proteinuria as surrogate endpoint, treatment burden and fatigue.

Insights captured (1)

Capture insight

INS-0049High
Patient-reported outcomes
Patient-reported outcomes: request for data reported by renal pathologist (US).
Closed

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Invite to advisory board

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 4
Depth of exchange: 4
Actionability: 5

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0142

Audit history (0)

All create, update and approval events for this record

No audit events in sample data